Expensive Drug Resistant TB Drugs Derail Treatment Efforts

People with drug-resistant tuberculosis (DR-TB) continue to be deprived of today’s best-possible treatment in part because of high drug prices, according to a new report—DR-TB Drugs Under the Microscope— released today by Doctors Without Borders (MSF) at the 49th Union World Conference on Lung Health in The Hague.   MSF called, in particular, on US pharmaceutical corporation Johnson & Johnson (J&J) to cut the price of the newer TB drug bedaquiline in half, so more lives can be Sed aved. In August 2018, the World Health Organization (WHO) recommended expanding…

Read More